Literature DB >> 22706853

The long and winding regulatory road for laboratory-developed tests.

Ronald L Weiss1.   

Abstract

"High complexity" clinical laboratories are approved under the Clinical Laboratory Improvement Amendments to develop, validate, and offer a laboratory-developed test (LDT) for clinical use. The Food and Drug Administration considers LDTs to be medical devices under their regulatory jurisdiction, and that at least certain LDTs should be subject to greater regulatory scrutiny. This review describes the current regulatory framework for LDTs and suggests ways in which to appropriately enhance this framework.

Mesh:

Year:  2012        PMID: 22706853     DOI: 10.1309/AJCP6OAULC3CMFEJ

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  4 in total

Review 1.  An overview of recommendations and translational milestones for genomic tests in cancer.

Authors:  Christine Q Chang; Sharna R Tingle; Kelly K Filipski; Muin J Khoury; Tram Kim Lam; Sheri D Schully; John P A Ioannidis
Journal:  Genet Med       Date:  2014-10-23       Impact factor: 8.822

Review 2.  Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics.

Authors:  Saumya Pant; Russell Weiner; Matthew J Marton
Journal:  Front Oncol       Date:  2014-04-17       Impact factor: 6.244

3.  A Difficult Challenge for the Clinical Laboratory: Accessing and Interpreting Manufacturer Cross-Reactivity Data for Immunoassays Used in Urine Drug Testing.

Authors:  Justine M Reschly-Krasowski; Matthew D Krasowski
Journal:  Acad Pathol       Date:  2018-11-21

Review 4.  Predicting the Uncertain Future of Aptamer-Based Diagnostics and Therapeutics.

Authors:  John G Bruno
Journal:  Molecules       Date:  2015-04-16       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.